Omnicell, Inc. - Common Stock (OMCL)

The healthcare tech company posted strong quarterly results.

Omnicell (OMCL) Q1 2025 Earnings Transcript

Omnicell OMCL Q2 2025 Earnings Transcript

Omnicell (OMCL) Q1 2026 Earnings Transcript

Healthcare tech company Omnicell (NASDAQ:OMCL) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 14.9% year on year to $3...

Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” or the “Company”), a leading healthcare technology provider focused on empowering autonomous medication management, today reported financial results for the first quarter ended March 31, 2026.

Healthcare tech company Omnicell (NASDAQ:OMCL) will be announcing earnings results this Tuesday before market hours. Here’s what to look for. Omnicell met an...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Omnicell (NASDAQ:OMCL) and it...

Omnicell, Inc. (Nasdaq:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the first quarter 2026, before market open on Tuesday, April 28, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

AINewsWire Editorial Coverage : As regulatory expectations intensify and manufacturing complexity grows, pharmaceutical companies are moving beyond traditional quality systems toward a new paradigm: embedding artificial intelligence (“AI”) directly into operations as a real-time compliance layer. Rather than relying on retrospective audits and manual oversight, AI-driven systems now continuously monitor, validate and optimize production processes to align with evolving Good Manufacturing Practice (“GMP”) standards. This structural shift is increasingly visible across the industry and aligns with companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ), which operate at the intersection of life sciences and advanced digital technologies, reflecting the broader movement toward intelligent, automated compliance frameworks. With its focus on AI, Oncotelic joins other AI-focused entities, including NVIDIA Corp. (NASDAQ: NVDA), Amazon.com Inc. (NASDAQ: AMZN), Honeywell International Inc. (NASDAQ: HON) and Omnicell Inc. (NASDAQ: OMCL), that are leading…

AUSTIN, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: As regulatory expectations intensify and manufacturing complexity grows, pharmaceutical companies are moving beyond traditional quality systems toward a new paradigm: embedding artificial intelligence (AI) directly into operations as a real-time compliance layer. Rather than relying on retrospective audits and manual oversight, AI-driven systems now continuously monitor, validate and optimize production processes to align with evolving Good Manufacturing Practice (GMP) standards. This structural shift is increasingly visible across the industry and aligns with companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile), which operate at the intersection of life sciences and advanced digital technologies, reflecting the broader movement toward intelligent, automated compliance frameworks. With its focus on AI, Oncotelic joins other AI-focused entities, including NVIDIA Corp. (NASDAQ: NVDA), Amazon.com Inc. (NASDAQ: AMZN), Honeywell International Inc. (NASDAQ: HON) and Omnicell Inc. (NASDAQ: OMCL), that are leading out in the space.

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

Over the past six months, Omnicell has been a great trade, beating the S&P 500 by 19.8%. Its stock price has climbed to $41.48, representing a healthy 26.4% ...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court ruled the previous week that the president could not use the International Emergency Economic Powers Act (IEEPA) for such duties, a decision that had initially sent markets higher. However, the administration invoked a different authority, the Trade Act of 1974, to impose a 15% global tariff for up to 150 days. The rapid reimposition of trade barriers creates significant uncertainty for companies across multiple sectors that depend on international supply chains and global trade. Investors are now weighing the potential impact of these new duties on corporate earnings and broader economic activity.

Omnicell’s fourth quarter was met with a significant negative market reaction, as the company delivered revenue in line with Wall Street expectations but posted a notable shortfall in non-GAAP profitability. Management attributed the quarter’s performance to robust demand for its point-of-care connected devices, particularly the XT S10, and highlighted strong annual recurring revenue momentum. However, mix shifts in product and customer base, as well as higher operating costs tied to new product introductions and customer experience initiatives, weighed on margins. CFO Baird Radford acknowledged that “non-GAAP EBITDA was at the lower end of our guidance,” citing deliberate investments in sales force expansion and innovation.

Healthcare tech company Omnicell (NASDAQ:OMCL) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 2.3% year on year to $314 million. The company expects next quarter’s revenue to be around $305 million, coming in 8.2% above analysts’ estimates. Its non-GAAP profit of $0.40 per share was 19.4% below analysts’ consensus estimates.

Shares of healthcare tech company Omnicell (NASDAQ:OMCL) fell 18.4% in the morning session after the company reported fourth-quarter earnings that fell short of Wall Street expectations and provided a disappointing forecast for the 2026 financial year. 

Omnicell (OMCL) Q4 2025 Earnings Call Transcript

Healthcare tech company Omnicell (NASDAQ:OMCL) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 2.3% year on year to $314 million. The company expects next quarter’s revenue to be around $305 million, coming in 8.2% above analysts’ estimates. Its non-GAAP profit of $0.40 per share was 19.4% below analysts’ consensus estimates.